Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 13/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.56 |
| ▸ | PPARA | Q07869 | 2/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | RXRA | P19793 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | RARG | P13631 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3117517 | 0.88 | PPARG (0.62) | PPARGFFAR1PPARAHRH3RXRA | |
| SCHEMBL68421 | 0.85 | PPARG (0.56) | PPARGFFAR1PPARAHRH3RXRA | |
| SCHEMBL6931933 | 0.84 | PPARG (0.56) | PPARGFFAR1PPARARXRACYP3A4 | |
| SCHEMBL9803889 | 0.83 | PPARG (0.64) | PPARGFFAR1PPARAHRH3RXRA | |
| SCHEMBL3900454 | 0.82 | FFAR1 (0.62) | PPARGFFAR1PPARAHRH3RXRA | |
| SCHEMBL9570670 | 0.81 | FFAR1 (0.71) | PPARGFFAR1PPARAHRH3RXRA | |
| SCHEMBL5883336 | 0.81 | PPARG (0.52) | PPARGFFAR1PPARAHRH3RXRA | |
| SCHEMBL2883389 | 0.80 | PPARG (0.56) | PPARGFFAR1PPARAHRH3RXRA | |
| SCHEMBL9803937 | 0.80 | PPARG (0.67) | PPARGFFAR1PPARAHRH3RXRA | |
| SCHEMBL1072226 | 0.80 | FFAR1 (0.77) | PPARGFFAR1PPARAHRH3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0919232-B1 | Composition for use in the treatment and prevention of hyperuricemia | SANKYO CO (JP) | 2004-10-06 | — | — | EP | claimed |
| US-20030149054-A1 | Administering thiazolidinedione derivatives for therapy and prophylaxis of cardiovascular diseases or eating disorders in a human or non- human mammal | BEECHAM GROUP P.L.C. | 2003-08-07 | — | — | US | claimed |
| EP-1306086-A2 | Use of thiazolidinediones for the treatment of atherosclerosis and eating disorders | SMITHKLINE BEECHAM PLC (GB) | 2003-05-02 | — | — | EP | claimed |
| US-20020049240-A1 | NOVEL COMPOUNDS | BEECHAM GROUP P.1.C. | 2002-04-25 | — | — | US | claimed |
| US-6353009-B1 | TREATMENT OF GOUT WITH ANTIINFLAMMATORY AGENTS | SANKYO COMPANY, LIMITED (JP) | 2002-03-05 | — | — | US | claimed |
| EP-0919232-A1 | Composition for use in the treatment and prevention of hyperuricemia | Sankyo Company Limited (JP) | 1999-06-02 | — | — | EP | claimed |
| EP-0842925-A1 | Substituted thiazolidinedione derivatives | BEECHAM GROUP PLC (GB) | 1998-05-20 | — | — | EP | claimed |
| EP-0695183-A1 | USE OF THIAZOLIDINEDIONES FOR THE TREATMENT OF ATHEROSCLEROSIS AND EATING DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 1996-02-07 | — | — | EP | claimed |
| WO-1994025026-A1 | USE OF THIAZOLIDINEDIONES FOR THE TREATMENT OF ATHEROSCLEROSIS AND EATING DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 1994-11-10 | — | — | WO | claimed |
| US-5232925-A | Treating hypertension | BEECHAM GROUP P.L.C. (GB) | 1993-08-03 | — | — | US | claimed |
| US-5002953-A | Substituted Thiazolidinedione Derivatives | BEECHAM GROUP P.L.C. (GB) | 1991-03-26 | — | — | US | claimed |
| EP-0306228-A1 | Substituted thiazolidinedione derivatives | BEECHAM GROUP PLC (GB) | 1989-03-08 | — | — | EP | claimed |
| US-11021751-B2 | Disease risk factors and methods of use | ZINFANDEL PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210095345-A1 | METHOD OF IDENTIFYING DISEASE RISK FACTORS | ZINFANDEL PHARMACEUTICALS INC (US) | 2021-04-01 | — | — | US | disclosed |
| US-10865449-B2 | Method of identifying disease risk factors | ZINFANDEL PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| EP-2789695-B1 | Anti-Alzheimer's disease treatment of subjects identified by detecting the presence of a genetic variant in the TOMM40 gene at rs 10524523 | ZINFANDEL PHARMACEUTICALS INC (US) | 2019-10-30 | — | — | EP | disclosed |
| US-5232925-A | Treating hypertension | BEECHAM GROUP P.L.C. (GB) | 1993-08-03 | — | — | US | disclosed |
| US-5194443-A | Thiazolinediones, Hypoglycemic Agents, Antilipemic Agents | BEECHAM GROUP P.L.C. (GB) | 1993-03-16 | — | — | US | disclosed |
| US-5002953-A | Substituted Thiazolidinedione Derivatives | BEECHAM GROUP P.L.C. (GB) | 1991-03-26 | — | — | US | disclosed |
| EP-0306228-A1 | Substituted thiazolidinedione derivatives | BEECHAM GROUP PLC (GB) | 1989-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149054-A1 | Administering thiazolidinedione derivatives for therapy and prophylaxis of cardiovascular diseases or eating disorders in a human or non- human mammal | TYK2, FABP3, FABP4 | PPARG 16/4885FFAR1 207/4885PPARA 20/4885 |
| US-20020049240-A1 | NOVEL COMPOUNDS | GRK1, GRK3, GRK7 | PPARG 715/4885FFAR1 1085/4885PPARA 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.